Bain Capital Life Sciences Investors LLC grew its holdings in shares of Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) by 96.1% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 7,911,669 shares of the company's stock after purchasing an additional 3,877,087 shares during the period. Solid Biosciences makes up approximately 4.3% of Bain Capital Life Sciences Investors LLC's holdings, making the stock its 7th largest position. Bain Capital Life Sciences Investors LLC owned approximately 10.21% of Solid Biosciences worth $29,273,000 as of its most recent SEC filing.
Several other large investors have also recently made changes to their positions in the business. Wells Fargo & Company MN lifted its holdings in shares of Solid Biosciences by 29.4% during the fourth quarter. Wells Fargo & Company MN now owns 13,138 shares of the company's stock valued at $53,000 after purchasing an additional 2,986 shares during the last quarter. Wellington Management Group LLP raised its holdings in Solid Biosciences by 4.0% in the 4th quarter. Wellington Management Group LLP now owns 124,551 shares of the company's stock worth $498,000 after acquiring an additional 4,747 shares during the last quarter. American Century Companies Inc. raised its holdings in Solid Biosciences by 10.6% in the 1st quarter. American Century Companies Inc. now owns 51,835 shares of the company's stock worth $192,000 after acquiring an additional 4,978 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Solid Biosciences by 8.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 68,607 shares of the company's stock worth $254,000 after acquiring an additional 5,220 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its holdings in Solid Biosciences by 80.7% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 15,308 shares of the company's stock worth $57,000 after acquiring an additional 6,836 shares during the last quarter. 81.46% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on SLDB. HC Wainwright restated a "buy" rating and issued a $20.00 price objective on shares of Solid Biosciences in a report on Tuesday, June 17th. Piper Sandler decreased their price objective on shares of Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating for the company in a report on Friday, May 16th. Chardan Capital restated a "buy" rating and issued a $15.00 price objective on shares of Solid Biosciences in a report on Thursday, August 14th. JPMorgan Chase & Co. decreased their target price on shares of Solid Biosciences from $15.00 to $13.00 and set an "overweight" rating for the company in a research note on Thursday, August 14th. Finally, Wedbush decreased their target price on shares of Solid Biosciences from $17.00 to $14.00 and set an "outperform" rating for the company in a research note on Wednesday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating and ten have given a Buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $15.00.
View Our Latest Stock Analysis on SLDB
Solid Biosciences Stock Performance
Shares of SLDB stock traded down $0.37 during mid-day trading on Monday, reaching $5.13. 435,916 shares of the company's stock traded hands, compared to its average volume of 1,832,450. Solid Biosciences Inc. has a 12 month low of $2.41 and a 12 month high of $8.45. The firm has a 50 day moving average price of $5.91 and a two-hundred day moving average price of $4.63. The firm has a market capitalization of $399.47 million, a PE ratio of -1.83 and a beta of 2.54.
Solid Biosciences (NASDAQ:SLDB - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.51) by $0.09. As a group, equities analysts expect that Solid Biosciences Inc. will post -2.84 earnings per share for the current fiscal year.
Solid Biosciences Company Profile
(
Free Report)
Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.
Further Reading

Before you consider Solid Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solid Biosciences wasn't on the list.
While Solid Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.